主たる論文 (1)

1) Fukusumi M, et al. Invasive pneumococcal disease among adults in Japan, April 2013 to March 2015: Disease characteristics and serotype distribution. BMC Infect Dis 2017 Jan 3;17(1):2.

2) Shimbashi R,et al. Epidemiological and clinical features of invasive pneumococcal disease caused by serotype 12F in adults, Japan. PLoS One 2019 Feb 21;14(2):e0212418.

3) Shimbashi R, et al. Effectiveness of 23-valent pneumococcal polysaccharide vaccine against invasive pneumococcal disease in adults, Japan 2013-2017. Emerg Infect Dis. 26(19): 2378-86,2020.

4) Chang B, et al. Distribution and variation of serotypes and pneumococcal surface protein A clades of Streptococcus pneumoniae strains isolated from adult patients with invasive pneumococcal disease in Japan. Front Cell Infect Microbiol. 2021, March 19; 11:617573.

5) Deloria Knoll M, Global landscape review of serotype-specific invasive pneumococcal disease Surveillance among countries using PCV10/13: The PSERENADE Project. Microorganisms. 9(4):742, 2021.

6) Garcia Quesada M, et al. Serotype distribution of remaining pneumococcal meningitis in the mature PCV10/13 period: Findings from the PSERENADE Project. Microorganisms. 9(4):738, 2021

主たる論文 (2)

7) Chang B, et al. Pneumococcal Meningitis in Adults in 2014-2018 after Introduction of Pediatric 13-valent Pneumococcal Conjugate Vaccine in Japan. Sci Rep 2022 Feb 23;12(1):3066.

8) Tamura K, et al. Dynamic changes in clinicalcharacteristics and serotype distribution of invasive pneumococcaldisease among adults in Japan after introduction of the pediatric 13-valent pneumococcal conjugate vaccine in 2013–2019． Vaccine 40:3338-44, 2022 doi: 10.1016/j.vaccine.2022.04.062.

9) Chang B, et al. Invasive Streptococcus oralis expressing serotype 3 pneumococcal capsule, Japan. Emerg Infect Dis 28（8）：1720-22，2022

10) Hachisu Y, et al. Invasive Haemophilus influenzae Disease among Adults in Japan during 2014–2018. Infection. 2022 Jul 28. doi: 10.1007/s15010-022-01885-w. Infection 51(2): 355-64, 2023.

11) Tamura K,et al. Unveiling the role of preceding seasonal influenza in the development of bacteremic pneumococcal pneumonia in older adults before the COVID-19 pandemic in Japan. 2024 Int J Infect Dis 143:107024.

主たる論文 (3)

12) Garcia Quesda M, et al. Serotype distribution of remaining invasive pneumococcal disease after extensive use of ten-valent and 13-valent pneumococcal conjugate vaccine (the PSERENADE project): a global surveillance analysis. Lancet Infect Dis 2025 25(4):445-456.

13) Bennet JC, et al. Global impact of 10- and 13-valent pneumococcal conjugate vaccines on pneumococcal diseases in all ages: The PSERENADE project. Lancet Infect Dis 2025 25(4):457-470.

14) Yang Y, et al. Global impact of 10- and 13-valent pneumococcal conjugate vaccines on pneumococcal meningitis in all ages: The PSERENADE project. J Infect 2025;90(3):106426.

研究班データ

2024 年の成人IPD 由来肺炎球菌の血清型分布(n=295)　NEW

成人IPD 由来肺炎球菌の血清型分布(n=3,034)　NEW

2023～24年のIPD原因血清型の検出割合が上位5種血清型の年次推移　NEW

髄膜炎由来肺炎球菌の感受性(n=404)　NEW

成人IPDの罹患率の変化：2017〜2024年　NEW

• 全年齢の罹患率は、COVID-19パンデミック前（2017–19年）と比較して、2020–22年に約60%減少し、2023–24
年にはわずかに増加した（約46％減少）
• ≥65歳の罹患率について、2024年（2.39）は2023年より僅かに増加した（パンデミック前より約44％減）。パンデミック対策緩和の影響と考えられるが、パンデミック前のレベルには戻っていない。
• パンデミック前にNVT（非ワクチン型）が増加し、PCV13固有血清型は減少した。PPSV23 固有血清型はほとんど変化はなかった。